Could your stomach meds be sabotaging cancer treatment?
NCT ID NCT07191171
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether certain drugs that change the gut bacteria (like antibiotics or acid reducers) can affect how well immunotherapy works in people with advanced lung cancer. Researchers will review medical records from 800 patients to see if those who took these drugs had different survival rates. The goal is to find ways to improve immunotherapy success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors choose which drugs to avoid alongside immunotherapy to improve lung cancer survival.
- What could go wrong
- This is a retrospective study, so it can only show links, not prove cause and effect. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSBIOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Pneumologie - CHU de Strasbourg - France
RECRUITINGStrasbourg, 67091, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Probiotics may reshape newborn gut health after C-Section or antibiotics
- Could a prebiotic diet boost brain development in preterm babies?
- Scientists probe immune cell shifts in ICU patients to unlock sepsis secrets
- Could poop transplants save sepsis patients?
- Beans for better bellies: new study tests pulse power in kids